TrialJournal of the National Cancer Institute2023

Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.

Joseph M Unger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.